MENLO PARK, Calif. — Ionpath, a pioneer in high-plex spatial proteomics, today announced the launch of its new service and data analysis tools for immuno-oncology applications in basic, translational, and clinical research. The service and analysis tools will be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 1-5 in San Diego, in the Ionpath exhibit hall booth (#1107).

Ionpath’s single-cell, spatial proteomics service utilizes its multiplexed ion beam imaging (MIBI™) technology, which uses mass spectrometry to query dozens of proteins with unmatched sensitivity and true subcellular resolution. The service offering, known as MIBIplus, launches with a human immuno-oncology panel that enables the detection of more than 40 relevant cell types in a single scan for a more complete view of the biological mechanisms in the tissue microenvironment affecting drug response, cancer progression, and more. Tissue samples are processed and run at Ionpath, and data is analyzed and returned to clients through a standardized report of actionable information. Ionpath’s new user-friendly analysis tool, MIBIsight, allows for iteration and customization of the standardized report by the customer to answer specific research questions.

“We’ve heard customers express high interest in a way to convert raw image data into actionable insights,” said David Summa, CEO of Ionpath. “In response, we are launching a new service offering, with user-friendly bioinformatic tools enabling scientists to take control of their data interpretation.”

The MIBIplus immuno-oncology service is now available for human tissue samples, and will soon be available for mouse samples as well. Projects can be completed from start to finish in two months or less. Special introductory pricing is available for new clients interested in learning how MIBI technology works with their samples through pilot projects.

To learn more about the immuno-oncology service, please visit our SITC booth (#1107) or our website: https://www.ionpath.com/mibiplus/.

About Ionpath

Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry, enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis. With MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.